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Objective: An elastic ventricular restraint device has been developed for patients with
heart failure who remain symptomatic despite treatment with standard therapies. The
safety and efficacy of this device are under clinical investigation. Six-month data for
the first 51 patients treated worldwide are reported. We hypothesize that the Paracor
HeartNet device (Paracor Medical, Sunnyvale, Calif), placed through a minithoracot-
omy in patients with severe dilated cardiomyopathy, improves clinical and functional
status.
Methods: Fifty-one patients with an ejection fraction of 35% or less, with a New York
Heart Association class II or III, and receiving optimal medical therapy for at least 3
months, were selected at 15 sites (3 in Europe, 12 in the United States) to undergo im-
plantation of the HeartNet device through a minithoracotomy. Patients were evaluated
at baseline and at 6-month follow-up by echocardiography, the 6-minute walk test,
cardiopulmonary exercise testing (partial oxygen pressure in mixed venous blood),
New York Heart Association class, and (in the United States) the Minnesota Living
with Heart Failure questionnaire.
Results: The average age was 52 years (30–73 years), with a preponderance of men
and nonischemic cause of heart failure. Implantation was accomplished in 50 of 51
patients (98%). Adverse events included 2 in-hospital deaths secondary to pulmonary
complications (4%), additional pulmonary complications in 7 patients (14%), arrhyth-
mia in 14 patients (27%), epicardial laceration in 2 patients (4%), and empyema in 1
patient (2%). Six-month data demonstrated significant improvement in the 6-minute
walk test (165.7, P5 .002) and Minnesota Living with Heart Failure scores (215.7,
P 5 .002) and improvement in echocardiographic findings.
Conclusion: The Paracor HeartNet device can be reliably implanted in patients with
heart failure and marked reduction of left ventricular function. These data suggest
a functional and clinical benefit, with a trend toward reverse remodeling, and support
the conduct of a randomized controlled pivotal trial.
O
ptimal heart failure therapy using neurohormonal blockade with angiotensin-
converting enzyme inhibitors and beta-blockers in all patients, and biventric-
ular pacing in certain patients who have prolonged QRS duration, represent
the current standard of care for patients with symptomatic systolic heart failure. De-
spite reductions in morbidity and mortality with medical therapy, there are some pa-
tients in whom optimal medical and device-based therapy fail to halt the progressive
course of this disease.1 In the current era, patients with end-stage heart failure are con-
sidered for destination therapy with a left ventricular assist device or heart transplan-
tation as a final option.2 Multiple therapies have been used or are under investigation
in an attempt to intervene earlier in the progression of this disease process. These ef-
forts have centered on surgically reshaping the ventricle or using biventricular pacing
to relieve mechanical and electrical asynchrony.3-10 Recently, other mechanical ther-
apies have been investigated to potentially halt the progression of the failing heart and
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LVEDD 5 left ventricular end-diastolic dimension
NYHA 5 New York Heart Association
allow for reverse remodeling in patients with stage C heart
failure to possibly attenuate progression to end-stage heart
failure.11 In a sheep model, it has been shown that a myocar-
dial constraint device can modify the left ventricular geome-
try after myocardial infarction.12-14 Myocardial constraint
devices have also been shown in an ovine model of tachycar-
dia-induced progressive dilated cardiomyopathy to improve
cardiac function, reduce left ventricular volume, and reduce
mitral regurgitation.15
The Paracor HeartNet device (Paracor Medical, Sunny-
vale, Calif) is an elastic ventricular restraint device that was
developed for patients with heart failure who remain symp-
tomatic with progressive cardiac remodeling or who continue
to remodel without concomitant clinical deterioration, de-
spite treatment with standard evidence-based therapies. It is
implanted around the heart to apply a low level of epicardial
pressure, thereby reducing wall stress and potentially induc-
ing reverse remodeling. The safety and efficacy of this device
are now under clinical investigation. We previously reported
the initial US experience with the device.16 This report details
the current worldwide surgical experience and 6-month fol-
low-up data for the first 51 patients treated and represents
a comprehensive and consecutive series of all patients im-
planted with the device worldwide.
It was hypothesized that the HeartNet device could be
safely implanted through a minithoracotomy in patients
with heart failure and significantly reduced left ventricular
systolic function and lead to improvement in clinical and
functional status.
Materials and Methods
Fifty-one patients with an ejection fraction of 35% or less, with New
York Heart Association (NYHA) class II or III, and receiving opti-
mal medical and or device therapy for at least 3 months were se-
lected at 15 sites (3 in Europe, 12 in the United States) to undergo
implantation of the HeartNet device through a minithoracotomy.
All US sites obtained investigational review board approval of the
Food and Drug Administration-approved safety and feasibility trial
and informed consent before patient enrollment. Criteria for enroll-
ment included patients with symptomatic heart failure (College of
Cardiology/American Heart Association stage C) caused by ische-
mic or nonischemic dilated cardiomyopathy and receiving stable
medical and device therapy for heart failure for at least 3 months.
This included pharmacologic therapy with angiotensin-converting
enzyme inhibitors or angiotensin II receptor blockers, as well as
beta-blockers, diuretics, and aldosterone inhibitors as tolerated.
An ejection fraction of less than or equal to 35% and receiving op-
timal medical and device therapy, including resynchronization ther-
apy as indicated, were additionally required for consideration.The Journal of ThoPatients with NYHA class IV heart failure, acute exacerbation of
symptoms, and previous cardiac operations were excluded. Left
ventricular end-diastolic dimension (LVEDD) of greater than 85
mmwas subsequently added as an exclusion criterion after initiation
of enrollment. Patients were evaluated at baseline and at 6-month
follow-up by echocardiography, 6-minute walk test, cardiopulmo-
nary exercise testing (partial oxygen pressure in mixed venous
blood), NYHA class, and (in the United States) the Minnesota
Living with Heart Failure questionnaire.
Operative Technique
All procedures were performed via a left anterior minithora-
cotomy under general anesthesia. Patients were positioned
supine, and fluoroscopy was used to identify the cardiac
apex. Minithoracotomy incision was performed 1 or 2 inter-
spaces lower than the apex to allow the correct trajectory for
the delivery system. Rib spreading was performed only to the
extent necessary to accommodate the introducer sheath. The
pericardium overlying the cardiac apex was opened and sus-
pended with stay sutures. The introducer was inserted into the
intrapericardial space and expanded (Figure 1, A). Frequently
the previously placed stay sutures were tensioned along the
introducer to keep the edges of pericardium from protruding
in the path to the cardiac apex. An unobstructed path to the
cardiac apex was ensured by direct visualization or by using
a 10-mm thoracoscope through the introducer. After confir-
mation of the introducer positioning, the delivery system
(Figure 1, B) was advanced through the introducer under
fluoroscopic guidance. The apex was captured with the suc-
tion cup while the device was inserted and deployed. Once
the delivery system was removed, either direct visualization
or the thoracoscope was used synergistically with fluoros-
copy to ensure appropriate device deployment and location
(Figure 2). The pericardium was loosely approximated, and
Figure 1. A, Introducer sheath used to maintain stable access to
pericardial space. B, HeartNet delivery system (Paracor Medical,
Sunnyvale, Calif).racic and Cardiovascular Surgery c Volume 135, Number 1 189
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accomplished in standard fashion.
Results
The HeartNet device was successfully implanted in 98% (50/
51) of the patients enrolled. The baseline demographics of the
patients are listed in Table 1. There was a preponderance of
male patients and those with a nonischemic cause of heart
failure. All patients had been receiving optimal medical ther-
apy for a minimum of 3 months. Clinical and functional
parameters (Table 2) and baseline echocardiographic data
(Table 3) demonstrated a moderately ill cohort of patients
with NYHA class II and III heart disease. Eight patients
(7 nonischemic, 1 ischemic) demonstrated greater than 21
mitral regurgitation on preoperative transthoracic echocar-
diography.
Procedural Data
Successful implantation was accomplished via a left anterior
minithoracotomy in 50 patients. In 1 patient, the tissue of the
pericardium and epicardium was determined to be extremely
friable. After an epicardial laceration necessitating suture
control, the procedure was aborted. In the 50 patients with
successful implantations, the average total anesthesia time
was 191 minutes (76–818 minutes, median 164 minutes),
although the skin incision to skin closure time averaged 78
minutes (26–233 minutes, median 73 minutes) (Table 4).
The actual time to deploy the device and the fluoroscopy
time constituted only a small part of the procedure duration.
Postoperative Course and Adverse Events
The average time to ambulation was 1.7 days (0–6 days, me-
dian 1 day), and the average intensive care unit stay was 2.9
days (1–16 days, median 2 days). The duration of patient
Figure 2. Paracor device implanted in heart model.190 The Journal of Thoracic and Cardiovascular Surgery c Janhospitalization averaged 8 days (3–29 days, median 6 days)
(Table 4). Perioperative pain-management strategy was se-
lected by the individual surgeon. Strategies included the
use of epidural catheters, intercostal nerve blocks, local anes-
thetic infusion pumps placed into the wound, and selected use
of ketorolac.
Serious adverse events (Table 5) included 2 patients with
unilateral diaphragmatic paresis and pleural effusion, 1
which resolved completely. One patient with diaphragmatic
paresis also presented for follow-up with anemia 1 month af-
ter implantation and was found to have colonic polyps. This
same patient returned a third time 3months after implantation
with a period of obtundation related to overmedication with
narcotics. One patient (2%) required reexploration for bleed-
ing secondary to persistently high chest tube outputs. At re-
exploration, the bleeding originated from an arterial branch
to the diaphragm. Fourteen patients had postprocedure ar-
rhythmias, including 8 patients who presented after discharge
TABLE 1. Baseline demographics
n (percent)/mean (range)
Parameter
n 5 51 unless otherwise
indicated
Age (y) 52.3 (30.4–72.6)
Male gender 48 (94%)
Race (white)* 47 (92%)
Cause
Nonischemic 41 (80%)
Ischemic 10 (20%)
Duration of heart failure (y) 6.2 (0.3–18.8)
Cardiac medications
ACEI/ARB 50 (98%)
Beta-blockers 49 (96%)
Coreg 33 (65%)
Metoprolol 14 (27%)
Diuretics (other than
spironolactone)
44 (86%)
Aldosterone inhibitors 30 (59%)
Digoxin 31 (61%)
Medical history and comorbidities
Systemic hypertension 22 (43%)
Pulmonary hypertension 17 (33%)
Diabetes mellitus 20 (39%)
Myocardial infarction 7 (14%)
Ventricular tachycardia 15 (29%)
Atrial fibrillation 14 (27%)
Biventricular pacemakery 2 (4%)
Biventricular ICDy 17 (33%)
Pacemaker aloney 0 (0%)
ICD aloney 14 (27%)
ACEI, Angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor
blocker; ICD, implantable cardioverter/defibrillator. *There were 3 African-
Americans (6%) and 1 Hispanic (2%). yOnly the active device was counted
for patients with a history of more than 1 type of device.uary 2008
Klodell Jr et al Evolving Technology
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for heart failure management and arrhythmia treatment.
Two patients sustained epicardial lacerations during the
procedure that required suture repair. In 1 patient the implan-
tation proceeded uneventfully after repair of the laceration. In
1 patient (2%) it was thought that the friable nature of the
epicardial and pericardial tissue precluded safe implantation
of the device, and the procedure was aborted.
Four patients had a total of 11 episodes of worsening heart
failure after implantation of the HeartNet device. Three of
these patients progressed to decompensated heart failure at
4, 8, and 22months after implantation of the HeartNet device.
TABLE 2. Baseline exercise and quality of life
n (percent)/mean (range)
Parameter n 5 51 unless otherwise indicated
NYHA class II* 18 (35%)
NYHA class III* 33 (65%)
Peak VO2 (mL/kg/min)y 16.4 (6.9–26.3)
n 5 49
VE/VCO2 slopey 32.1 (22.0–59.0)
n 5 36
6MWT (m) 360.2 (108.0–523.0)
MLHF (units)z 56.4 (23.0–91.0)
n 5 38
NYHA, New York Heart Association; 6MWT, 6-minute walk test;MLHF,Min-
nesota Living with Heart Failure; VE, ventilation; VCO2, carbon dioxide out-
put. *For NYHA class, because an independent assessment was not done
for European patients, site assessment was used. yFor Peak VO2 and VE/
VCO2 slope, if core laboratory data were not available for European patients,
the site assessment was used. zFor MLHF, these data were only collected at
US sites.
TABLE 3. Baseline echocardiographic parameters
Parameter
Mean (range) unless
otherwise indicated
LVEF (%) 22.1 (11.0–33.7)
n 5 49
LVEDD (mm) 7.3 (5.4–9.8)
n 5 46
LVESD (mm) 6.3 (4.2–8.8)
n 5 46
Diastolic LV volume (cm3) 352.7 (193.2–651.5)
n 5 49
Systolic LV volume (cm3) 278.3 (134.0–559.3)
n 5 49
MR . 21 (No. of patients) 8 patients (17%)
n 5 47
Diastolic sphericity index ratio* 0.6 (0.3–0.9)
n 5 49
LVEF, Left ventricular ejection fraction; LVEDD, left ventricular end-diastolic
dimension; LVESD, left ventricular end-systolic dimension; LV, left ventricu-
lar; MR, mitral regurgitation; EDV, end-diastolic volume; EDL, end-diastolic
length. *Diastolic Sphericity 5 EDV/p $ EDL3/6.The Journal of ThorVentricular assist device placement was required in these
3 patients and was accomplished without incident.
Major adverse events (Table 5) included 2 deaths during
the initial hospitalization and within 30 days of procedure
(overall in-hospital and 30 day mortality was 4%). One
patient had significant pulmonary dysfunction and methi-
cillin-resistant Staphylococcus aureus pneumonia requiring
reintubation. The patient progressed to multisystem organ
failure and died on postoperative day 16. Postmortem exam-
ination confirmed severe bilateral necrotizing pneumonia and
evidence of necrotizing pancreatitis. There was no evidence
of device malfunction, nor was the device implicated as the
cause of death. The pericardial adhesions to the device
were noted to be mild. Pneumonia developed in 1 patient
who required reintubation and had a period of hemodynamic
instability requiring vasopressors. This progressed to multi-
system organ failure, and the patient died on postoperative
day 14. Postmortem examination showed evidence of gastro-
intestinal hemorrhage and bilateral lower lobe consolidation
of the lungs. The report did not comment on density of intra-
pericardial adhesions to the device. These 2 patients had the
largest LVEDDs in this series (90 mm and 94 mm, respec-
tively). After the deaths of these 2 patients with large
LVEDDs, patients with an LVEDD greater than 85 mm or
TABLE 4. Index procedural information for 51 patients
(range)
Mean 6 SD (range)
Parameter Median
Anesthesia time (min)* 190.6 6 114.3 (76.0–818.0)
164.0
n 5 49
Skin to skin (min)* 77.7 6 39.9 (26.0–233.0)
73.0
n 5 51
Fluoroscopy time (min) 8.8 6 8.9 (1.4–52.0)
6.1
n 5 50
Implant time (min) 19.8 6 21.6 (4.0–108.0)
12.0
n 5 49
Time to ambulation (d) 1.7 6 1.2 (0–6.0)
1.0
n 5 41
ICU length of stay (d) 2.9 6 3.0 (1.0–16.0)
2.0
n 5 51
Hospital length of stay (d) 8.0 6 5.0 (3.0–29.0)
6.0
n 5 51
SD, Standard deviation; ICU, intensive care unit. *Anesthesia time is defined
as time from induction of anesthesia to patient consciousness. One patient
did not receive an implant, but this patient's anesthesia (147 minutes) and
skin to skin (101 minutes) times are included in the table.acic and Cardiovascular Surgery c Volume 135, Number 1 191
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implantation of the HeartNet device. There were no subse-
quent early deaths.
Functional parameters showed significant improvement at
6 months in the 6-minute walk test (mean increase 65.7 m,
TABLE 5. Adverse events
Adverse event No. of events No. of patients
Death* 3 3
Reoperation for bleedingy 1 1
Arrhythmias, bradycardias,
and tachycardias
17 14
Laceration 2 2
Pericarditis 1 1
Worsening heart failurez 11 4
Anemia 3 2
Obtundation/altered mental status 1 1
Phrenic nerve injury 2 2
Stroke/transient ischemic attack 2 1
Dyspnea, shortness of breath 1 1
Pleural effusion 4 3
Pneumothorax 1 1
Respiratory failure/atelectasis/
pneumonia
2 2
Empyema 1 1
Renal insufficiency/failure/
compromise
2 2
*Two deaths occurred in-hospital and within 30 days, and 1 death occurred
8 months after implant. yBleeding secondary to diaphragmatic source; no
intrapericardial bleeding. zThree patients have ultimately required ventric-
ular assist devices for worsening heart failure at 4, 8, and 22 months after
implantation of the HeartNet device.192 The Journal of Thoracic and Cardiovascular Surgery c JanP 5 .002, n 5 36) and Minnesota Living with Heart Failure
score (mean decrease 15.7 units , P5 .002, n5 26 (US only)
when compared with baseline (Figure 3). The peak volume of
oxygen use (n 5 35) demonstrated a trend toward improve-
ment but did not reach significance at the 6-month interval.
It is known that cardiopulmonary exercise testing is a com-
plex test with many confounding factors, requiring further
analysis and study of this result.
Echocardiographic parameters also demonstrated sig-
nificant improvement at the 6-month interval (n 5 39, 39
eligible patients, 100% follow-up) with improvements in
LVEDD (mean decrease 3 mm, P5 .038), end-diastolic vol-
ume (mean decrease 25.7 cm3, P 5 .025), end-systolic
volume (mean decrease 23.5 cm3, P5 .037), and left ventric-
ular mass (mean decrease 23.1 g, P 5 .046). The trends in
NYHA class paralleled the findings of functional and echo-
cardiographic improvement (Figure 4).
Discussion
This report summarizes the current worldwide experience
with the Paracor HeartNet device during the Safety and Fea-
sibility trial of this myocardial constraint device. Previous
reports have detailed the archetype myocardial constraint
device: the Acorn CorCap (Acorn Cardiovascular, St Paul,
Minn).11,17 The Paracor HeartNet device differs from the
CorCap device in several important ways. The HeartNet de-
vice is delivered via a minimal access left thoracotomy inside
the pericardium with the aid of an introducer and delivery
system, and adheres to the heart because of small textured
areas on the epicardial side of the device. The pericardium re-
maining intact around the heart has an unknown effect on the
long-term progression of the disease process, but may facili-
tate future cardiac surgery. The HeartNet device currently hasFigure 3. 6MWTand MLHF change from
baseline to 6 months. 6MWT, 6-minute
walk test; MLHF, Minnesota Living
with Heart Failure; SD, standard devia-
tion. *P value forMLHF calculated using
Wilcoxon signed-rank test; t test was
used for all other parameters.uary 2008
Klodell Jr et al Evolving TechnologyFigure 4. New York Heart Class change from
baseline. NYHA, New York Heart Association.ET16 sizes available and is sized by echo parameters, in theory
making the fit consistent over a large size range. This pre-pro-
cedure sizing based on objective criteria should allow for re-
producible fit to the myocardium and reproducible results. It
is also constructed of a nitinol mesh, which is both compliant
and elastic. The relatively large compliance range reduces the
likelihood of developing a constrictive-type physiology, al-
though the elasticity may provide some positive epicardial
pressure that may be beneficial compared with the non-elastic
construction of the CorCap device. A recently published
ovine study noted that the optimal physiologic restraint level
of 3 mm Hg was identified to maximize improvement with-
out an adverse affect on systemic hemodynamics.18 The niti-
nol mesh may have an additional benefit of reduced adhesion
formation when compared with other materials, although fur-
ther study will be required. It is known that in the patients
who have developed progressive heart failure and required
ventricular assist devices (n5 3), the devices were implanted
uneventfully. Reports from the implanting surgeons (1 Heart-
Net investigator, 2 not involved in the study) detailed moder-
ate adhesions over the apex of the left ventricle at the site of
the pericardial opening, but otherwise mild adhesions. This
may ultimately prove a dramatic advantage to this type of de-
vice, because some of these patients inevitably will require
either assist devices or cardiac transplantation. Further study
of the device will help to better elucidate these advantages
over other ventricular restraint devices, such as the CorCap
or cardiomyoplasty procedures.
Class IV heart failure and adhesions from previous cardiac
operations were considered as exclusions for the initial safety
and feasibility trial of the HeartNet device. This may have led
to a selection bias of a greater number of nonischemic
patients with heart failure. It is unclear at this time what the
impact of these exclusions would be on the eventual clinical
adaptation of this device. In addition, longer follow-up willThe Journal of Thorbe required to determine the effect of device implantation
on patients with greater than 21mitral regurgitation (n5 8).
This report demonstrates that the HeartNet device can be
implanted with a high degree of surgical success (98%) in
patients with heart failure and reduction of left ventricular
function. The surgical implantation procedure was relatively
straightforward with only 2 intraoperative complications and
a single patient with significant postoperative bleeding. Ma-
jor adverse events occurred in the 2 patients with the largest
hearts as measured by end-diastolic dimension. This early ex-
perience indicates that, as with the CorCap, the patients with
the largest end-diastolic dimensions are not optimal candi-
dates for this therapy. In the remaining patients, the post-
operative course parallels what might be expected after any
thoracotomy in this moderately severe ill patient cohort.
Also similar to post-thoracotomy care, adequate preoperative
pulmonary evaluation and excellent postoperative pain con-
trol seem to be paramount to success. The 6-month paired
data suggest a functional and clinical benefit, with a trend
toward reverse remodeling, and support the conduct of a
randomized controlled pivotal trial (Prospective Evaluation
of Elastic Restraint to LESSen the effects of Heart Failure),
which has begun enrollment in the United States.
References
1. Packer M. The impossible task of developing a new treatment for heart
failure. J Card Fail. 2002;8:193-6.
2. Slaughter MS. Destination therapy: the future is arriving. Congest Heart
Fail. 2005;11:155-6.
3. Chen FY, Cohn LH. The surgical treatment of heart failure. A new fron-
tier: nontransplant surgical alternatives in heart failure. Cardiol Rev.
2002;10:326-33.
4. Loebe M, Soltero E, Thohan V, Lafuente JA, Noon GP. New surgical
therapies for heart failure. Curr Opin Cardiol. 2003;18:194-8.
5. Acker MA. Surgical therapies for heart failure. J Card Fail. 2004;
10(6 Suppl):S220-4.
6. Auricchio A, Stellbrink C, Block M, Sack S, Vogt J, Bakker P, et al.
Effect of pacing chamber and atrioventricular delay on acute systolicacic and Cardiovascular Surgery c Volume 135, Number 1 193
Evolving Technology Klodell Jr et al
ETfunction of paced patients with congestive heart failure. The Pacing
Therapies for Congestive Heart Failure Study Group. The Guidant
Congestive Heart Failure Research Group. Circulation. 1999;99:
2993-3001.
7. Abraham WT, Hayes DL. Cardiac resynchronization therapy for heart
failure. Circulation. 2003;108:2596-603.
8. Abraham WT, Young JB, Leon AR, Adler S, Bank AJ, Hall SA, et al.
Effects of cardiac resynchronization on disease progression in patients
with left ventricular systolic dysfunction, an indication for an implant-
able cardioverter-defibrillator, and mildly symptomatic chronic heart
failure. Circulation. 2004;110:2864-8.
9. Aranda JM Jr,WooGW, Conti JB, Schofield RS, Conti CR, Hill JA. Use
of cardiac resynchronization therapy to optimize beta-blocker therapy in
patients with heart failure and prolonged QRS duration. Am J Cardiol.
2005;95:889-91.
10. Aranda JM Jr, Woo GW, Schofield RS, Handberg EM, Hill JA,
Curtis AB, et al. Management of heart failure after cardiac resynchroni-
zation therapy: integrating advanced heart failure treatment with optimal
device function. J Am Coll Cardiol. 2005;46:2193-8.
11. Walsh RG. Design and features of the Acorn CorCap Cardiac Support
Device: the concept of passive mechanical diastolic support. Heart
Fail Rev. 2005;10:101-7.
12. Blom AS, Mukherjee R, Pilla JJ, Lowry AS, Yarbrough WM,
Mingoia JT, et al. Cardiac support device modifies left ventricular geom-
etry and myocardial structure after myocardial infarction. Circulation.
2005;112:1274-83.
13. Blom AS, Pilla JJ, Gorman RC 3rd, Gorman JH, Mukherjee R,
Spinale FG, et al. Infarct size reduction and attenuation of global left ven-
tricular remodeling with the CorCap cardiac support device following
acute myocardial infarction in sheep. Heart Fail Rev. 2005;10:125-39.
14. Cheng A, Nguyen TC, Malinowski M, Langer F, Liang D,
Daughters GT, et al. Passive ventricular constraint prevents transmural
shear strain progression in left ventricle remodeling. Circulation.
2006;114(1 Suppl):I79-86.
15. Power JM, Raman J, Byrne MJ, Alferness CA. Efficacy of the Acorn
Cardiac Support Device in animals with heart failure secondary to
high rate pacing. Heart Fail Rev. 2005;10:117-23.
16. Klodell CT Jr, McGiffin DC, Rayburn BK, Sun B, Abraham WT,
Conte JV, et al. Initial United States experience with the Paracor Heart-
Net myocardial constraint device for heart failure. J Thorac Cardiovasc
Surg. 2007;133:204-9.
17. Acker MA. Clinical results with the Acorn cardiac restraint device with
and without mitral valve surgery. Semin Thorac Cardiovasc Surg. 2005;
17:361-3.
18. Ghanta RK, Rangaraj A, Umakanthan R, Lee L, Laurence RG, Fox JA,
et al. Adjustable, physiological ventricular restraint improves left ven-
tricular mechanics and reduces dilatation in an ovine model of chronic
heart failure. Circulation. 2007;115:1201.
Discussion
DrM. Acker (Philadelphia, Pa). I congratulate you on this feasibil-
ity study and the honest reporting of all of the complications. What I
found most interesting in your talk is actually the slide that com-
pared the compliance of the Paracor device with the CorCap and
pericardium and how unbelievably low it is, and yet still I guess
the theory is that this amount of push-back on diastolic stress is still
enough to have a biological effect. We don’t know what that limit is
because the Paracor almost seems to have no push-back compared
with the other membranes around the heart. I wonder if you would
comment on that.
Dr Klodell. Thank you for that excellent question, Dr Acker.
I think that is exactly true. It is a very interesting concept to think
about. I am sure, as you are aware and I will point out for the audi-
ence, in the early March issue of Circulation the Brigham group
published their results on an ovine model looking at the optimal epi-
cardial pressure that did not result in hemodynamic compromise but194 The Journal of Thoracic and Cardiovascular Surgery c Jandid perhaps promote reverse remodeling, which was approximately
3 mm Hg of epicardial pressure in their study, and that is fairly con-
sistent with what the Paracor device provides. So it may be that this
is about the right amount of epicardial pressure.
Dr M. Anstadt (Dayton, Ohio). I have a question about the im-
plications on diastolic dysfunction. Clearly, the girdling effect of
these passive constraint devices is beneficial for systolic function.
If you examine the basic research around constraint devices, both
passive and active, there are implications that diastolic function
can be impaired, particularly if you look at the right. Now that we
have these clinical studies ongoing, what is being done to assess di-
astolic function after device implantation, particularly in the right
ventricle? You mentioned that you can image these hearts echo-
cardiographically, and with new imaging techniques, ventricular
inhibited [pacemaker], and so forth, we have a critically important
opportunity. Obviously diastolic dysfunction may have contributed
to your reported deaths in these larger hearts. Do you think that con-
straint devices have a negative impact on diastolic function that can
significantly exacerbate the underlying diastolic dysfunction of
heart failure?
Dr Klodell. It is unknown, as you pointed out right now, what
the long-term effects on diastolic dysfunction are going to be. One
of the advantages, again, of this device may be the fact that it is
more compliant and that it triggers whatever neurohormonal signals
there are for the reverse remodeling. Perhaps it will have a beneficial
effect, but I hope the Pivotal Trial is going to answer that question.
I think as far as your comment about the 2 deaths, that is
an interesting thing to consider, although I believe that the 2 deaths
were completely due to patient selection. They were patients who
had a preexisting pulmonary dysfunction, and they did have partic-
ularly large hearts. Trouble began early, they had to be reintubated,
and they spiraled into multisystem organ failure related to their
pulmonary dysfunction.
Dr A. Elami (Jerusalem, Israel). I am referring to a letter to the
editor published 3 months ago in The Journal of Thoracic and Car-
diovascular Surgery regarding a similar device, the CorCap. The
questions raised in this letter were left open, however, and I would
like to raise them again.
I believe everybody in this room is familiar with the echocardio-
graphic appearance of the globally enlarged ventricle in these pa-
tients, especially the bulge of the ventricular septum into the right
side. Your device does not address the septum at all. What is the
mechanism by which you are expecting this device to influence
the septum if it is not addressed by the device? This is the first
question.
The second question is with regard to the systolic interaction
between the device and the heart. We all know that the pressures
in the right side of the heart are much lower than in the left side.
Now during systole, assuming that the tension of the device is
equal and evenly distributed around the heart, why should it pre-
vent the left ventricle from expanding rather than squeeze the
lower pressure right ventricle? What is the mechanism of action
during systole?
Dr Klodell. As far as addressing the septum, you are abso-
lutely correct, none of the restraint devices, meaning the CorCap
or this device, directly address the septum, and again, I think there
is a complex interplay between the potential for systolic augmen-
tation by direct epicardial pressure and neurohormonal remodeling
that goes on. These devices are being used in patients who haveuary 2007
Klodell Jr et al Evolving Technologyongoing clinical deterioration or progressive remodeling without
clinical deterioration. It is unknown how to stop that progress,
but it is known what the consequences are if those patients’ clin-
ical condition continues to progress. It is important to realize the
proposed effect of these devices is thought to involve the complex
interplay of the neurohormonal signals for reverse remodeling, not
direct mechanical effects.
As far as the systolic interaction, again, the epicardial pressure
generated by these devices is very low. Even once the device is
on, you can very easily slip a finger underneath it, and it is compliantThe Journal of Thorenough that it does not have but 3 or 4 mm of direct pressure on the
epicardium. So we have not seen that interplay with the right ventri-
cle to be a problem at this point.
DrM. Acker.We have to move on. As far as that question goes,
this is not a mechanical effect. A mechanical effect is a signal to start
a change in the phenotype at a cellular level, and that gives the neu-
rohormonal changes, and this has been shown well by Tony Sabbah.
So it is not just the girdling effect. That is how the septum gets better.
It is the neurohormonal cascade that is started by this pressure that is
exerted during diastole.acic and Cardiovascular Surgery c Volume 135, Number 1 195
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